Nexium Delayed-Release Capsules had sales of $6 billion in the US last year.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has announced that it has received Food and Drug Administration (FDA) approval for the first generic equivalent to Nexium (esomeprazole magnesium) Delayed-Release Capsules in the United States. Nexium is used to treat symptoms of gastroesophageal reflux disease (GERD) and other conditions involving excessive stomach acid such as Zollinger-Ellison syndrome.
Teva says that it is preparing to launch the product in the near future.
Nexium Delayed-Release Capsules, marketed by AstraZeneca, had annual sales of approximately $6 billion in the US, according to IMS data as of November 2014.
Published by Globes [online], Israel business news - www.globes-online.com - on January 27, 2015
© Copyright of Globes Publisher Itonut (1983) Ltd. 2015
Teva picture: Bloomberg